Advertisement

Topics

FDA Accepts BLA for Proposed Biosimilar to Biogen's Rituxan

06:20 EDT 30 Jun 2017 | PharmPro

Celltrion and Teva announce U.S. FDA acceptance of Biologics License Application for proposed biosimilar to Rituxan (rituximab). FDA regulatory action is expected during the first quarter of 2018.
Contributed Author: 
Celltrion, Inc.

Original Article: FDA Accepts BLA for Proposed Biosimilar to Biogen's Rituxan

NEXT ARTICLE

More From BioPortfolio on "FDA Accepts BLA for Proposed Biosimilar to Biogen's Rituxan"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...